{
  "version": "2.0",
  "last_updated": "2026-02-14",
  "sources": [
    {
      "id": "AHA2022",
      "title": "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure",
      "doi": "10.1161/CIR.0000000000001063"
    },
    {
      "id": "AHA2023",
      "title": "2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Reduced Ejection Fraction",
      "doi": "10.1016/j.jacc.2023.10.024"
    },
    {
      "id": "ESC2021",
      "title": "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure",
      "doi": "10.1093/eurheartj/ehab368"
    },
    {
      "id": "ESC2023",
      "title": "2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure",
      "doi": "10.1093/eurheartj/ehad195"
    },
    {
      "id": "ESC2024",
      "title": "2024 ESC Guidelines for the management of chronic and acute heart failure",
      "doi": "10.1093/eurheartj/ehae600"
    },
    {
      "id": "ECDP2024",
      "title": "2024 ACC Expert Consensus Decision Pathway for SGLT2 Inhibitors",
      "doi": "10.1016/j.jacc.2024.01.001"
    }
  ],
  "rules": [
    {
      "rule_id": "R-001",
      "guideline_id": "AHA2022-001",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFrEF"],
      "description": "ARNI recommended for HFrEF to reduce morbidity and mortality",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40,
        "requires_current_acei_arb": false
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-002",
      "guideline_id": "ESC2021-001",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFrEF"],
      "description": "ARNI recommended as replacement for ACEi in HFrEF (stronger preference than AHA)",
      "class": "I",
      "loe": "B-R",
      "conditions": {
        "ef_max": 40,
        "note": "ESC prefers ARNI over ACEi more strongly than AHA"
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-003",
      "guideline_id": "AHA2022-002",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFmrEF"],
      "description": "ARNI may be considered in HFmrEF",
      "class": "IIb",
      "loe": "B-NR",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-003b",
      "guideline_id": "AHA2022-002b",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFmrEF"],
      "description": "ACEi/ARB may be considered in HFmrEF",
      "class": "IIb",
      "loe": "B-NR",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-004",
      "guideline_id": "AHA2022-003",
      "pillar": "BETA_BLOCKER",
      "ef_categories": ["HFrEF"],
      "description": "Evidence-based beta-blocker for HFrEF to reduce morbidity and mortality",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "hr_low": 60,
        "bp_low_sbp": 90
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-005",
      "guideline_id": "ESC2021-002",
      "pillar": "BETA_BLOCKER",
      "ef_categories": ["HFrEF"],
      "description": "Evidence-based beta-blocker for HFrEF",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "hr_low": 60,
        "bp_low_sbp": 90
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-006",
      "guideline_id": "AHA2022-004",
      "pillar": "BETA_BLOCKER",
      "ef_categories": ["HFmrEF"],
      "description": "Beta-blocker may be considered in HFmrEF",
      "class": "IIb",
      "loe": "B-NR",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "hr_low": 60,
        "bp_low_sbp": 90
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-007",
      "guideline_id": "AHA2022-005",
      "pillar": "MRA",
      "ef_categories": ["HFrEF"],
      "description": "MRA recommended for HFrEF NYHA II-IV to reduce morbidity and mortality",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40,
        "nyha_min": 2
      },
      "thresholds": {
        "k_high": 5.0,
        "egfr_init": 30,
        "egfr_cont": 20
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-008",
      "guideline_id": "ESC2021-003",
      "pillar": "MRA",
      "ef_categories": ["HFrEF"],
      "description": "MRA recommended for HFrEF to reduce hospitalization and death",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "k_high": 5.0,
        "egfr_init": 30,
        "egfr_cont": 20
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-009",
      "guideline_id": "AHA2022-006",
      "pillar": "MRA",
      "ef_categories": ["HFmrEF"],
      "description": "MRA may be considered in HFmrEF",
      "class": "IIb",
      "loe": "B-NR",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "k_high": 5.0,
        "egfr_init": 30,
        "egfr_cont": 20
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-010",
      "guideline_id": "AHA2022-007",
      "pillar": "SGLT2i",
      "ef_categories": ["HFrEF"],
      "description": "SGLT2i recommended for HFrEF to reduce hospitalization and CV death",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-011",
      "guideline_id": "ESC2021-004",
      "pillar": "SGLT2i",
      "ef_categories": ["HFrEF"],
      "description": "SGLT2i recommended for HFrEF",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-012",
      "guideline_id": "AHA2022-008",
      "pillar": "SGLT2i",
      "ef_categories": ["HFmrEF"],
      "description": "SGLT2i can be beneficial in HFmrEF",
      "class": "IIa",
      "loe": "B-R",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-013",
      "guideline_id": "AHA2022-009",
      "pillar": "SGLT2i",
      "ef_categories": ["HFpEF"],
      "description": "SGLT2i can be beneficial in HFpEF (AHA: Class 2a)",
      "class": "IIa",
      "loe": "B-R",
      "conditions": {
        "ef_min": 50,
        "note": "AHA grades HFpEF SGLT2i as Class 2a, LOE B"
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-014",
      "guideline_id": "ESC2023-001",
      "pillar": "SGLT2i",
      "ef_categories": ["HFpEF"],
      "description": "SGLT2i recommended in HFpEF (ESC: Class I â€” stronger than AHA)",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_min": 50,
        "note": "ESC 2023 Focused Update grades HFpEF SGLT2i as Class I, LOE A"
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehad195"
    },
    {
      "rule_id": "R-015",
      "guideline_id": "ECDP2024-001",
      "pillar": "SGLT2i",
      "ef_categories": ["HFrEF", "HFmrEF", "HFpEF"],
      "description": "SGLT2i across HF spectrum with specific eGFR guidance",
      "class": "I",
      "loe": "A",
      "conditions": {
        "note": "ACC ECDP 2024 provides agent-specific eGFR guidance for SGLT2i"
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1016/j.jacc.2024.01.001"
    },
    {
      "rule_id": "R-016",
      "guideline_id": "ESC2024-001",
      "pillar": "MRA",
      "ef_categories": ["HFmrEF", "HFpEF"],
      "description": "Finerenone may be considered in HFmrEF/HFpEF with T2DM (ESC 2024)",
      "class": "IIa",
      "loe": "B-R",
      "conditions": {
        "ef_min": 41,
        "requires_dm_type2": true,
        "note": "Finerenone for HFmrEF/HFpEF based on FINEARTS-HF. AHA not yet graded."
      },
      "thresholds": {
        "k_high": 5.0,
        "egfr_init": 25,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehae600"
    },
    {
      "rule_id": "R-017",
      "guideline_id": "ESC2023-002",
      "pillar": "SGLT2i",
      "ef_categories": ["HFmrEF"],
      "description": "SGLT2i recommended in HFmrEF (ESC: Class I)",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehad195"
    },
    {
      "rule_id": "R-018",
      "guideline_id": "ESC2021-005",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFmrEF"],
      "description": "ARNI may be considered in HFmrEF (ESC)",
      "class": "IIb",
      "loe": "C-LD",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-018b",
      "guideline_id": "ESC2021-005b",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFmrEF"],
      "description": "ACEi/ARB may be considered in HFmrEF (ESC)",
      "class": "IIb",
      "loe": "C-LD",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-021",
      "guideline_id": "AHA2022-010",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFrEF"],
      "description": "ACEi recommended for HFrEF when ARNI is not tolerated or accessible",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1161/CIR.0000000000001063"
    },
    {
      "rule_id": "R-022",
      "guideline_id": "ESC2021-008",
      "pillar": "ARNI_ACEi_ARB",
      "ef_categories": ["HFrEF"],
      "description": "ACEi/ARB for HFrEF when ARNI not tolerated (ESC)",
      "class": "I",
      "loe": "A",
      "conditions": {
        "ef_max": 40
      },
      "thresholds": {
        "bp_low_sbp": 100,
        "egfr_init": 20,
        "egfr_cont": 15
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-019",
      "guideline_id": "ESC2021-006",
      "pillar": "BETA_BLOCKER",
      "ef_categories": ["HFmrEF"],
      "description": "Beta-blocker may be considered in HFmrEF (ESC)",
      "class": "IIb",
      "loe": "C-LD",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "hr_low": 60,
        "bp_low_sbp": 90
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    },
    {
      "rule_id": "R-020",
      "guideline_id": "ESC2021-007",
      "pillar": "MRA",
      "ef_categories": ["HFmrEF"],
      "description": "MRA may be considered in HFmrEF (ESC)",
      "class": "IIb",
      "loe": "C-LD",
      "conditions": {
        "ef_min": 41,
        "ef_max": 49
      },
      "thresholds": {
        "k_high": 5.0,
        "egfr_init": 30,
        "egfr_cont": 20
      },
      "source_doi": "10.1093/eurheartj/ehab368"
    }
  ],
  "pillar_thresholds": {
    "ARNI_ACEi_ARB": {
      "bp_low_sbp": 100,
      "egfr_init": 20,
      "egfr_cont": 15
    },
    "BETA_BLOCKER": {
      "hr_low": 60,
      "bp_low_sbp": 90
    },
    "MRA": {
      "k_high": 5.0,
      "egfr_init": 30,
      "egfr_cont": 20
    },
    "SGLT2i": {
      "egfr_init": 20,
      "egfr_cont": 15
    }
  },
  "stale_data_thresholds": {
    "labs_max_days": 14,
    "vitals_max_days": 30
  },
  "multi_guideline_differences": [
    {
      "topic": "SGLT2i in HFpEF",
      "aha": { "class": "IIa", "loe": "B-R", "rule_id": "R-013" },
      "esc": { "class": "I", "loe": "A", "rule_id": "R-014" },
      "display": "AHA: Class 2a, LOE B | ESC: Class I, LOE A"
    },
    {
      "topic": "Finerenone in HFmrEF/HFpEF",
      "aha": { "class": null, "loe": null, "rule_id": null },
      "esc": { "class": "IIa", "loe": "B-R", "rule_id": "R-016" },
      "display": "ESC: Class IIa, LOE B (FINEARTS-HF) | AHA: Not yet graded"
    },
    {
      "topic": "ARNI vs ACEi first-line in HFrEF",
      "aha": { "note": "Class I for both ARNI and ACEi (can use either)" },
      "esc": { "note": "ARNI preferred over ACEi (stronger recommendation)" },
      "display": "AHA: ARNI or ACEi (Class I) | ESC: Prefer ARNI over ACEi"
    }
  ]
}
